Clinical Coordinators: Your Thread Is the Compliance Record

The protocol is PDF. The argument is still email.

Clinical operations teams do not get to romanticize their tooling. When an FDA guidance document explicitly contemplates email as a routine channel between sponsors and review staff, and center SOPPs describe email for regulatory communications with expectations about completeness, the inbox stops being "informal." It becomes part of the administrative file everyone will reconstruct two years later during an inspection. That is why coordinators forward IRB letters, data queries, and monitor visit notes the way they do: the thread is the narrative.

The work is not glamorous. It is forty-message chains about inclusion criteria, lab slips that arrived late, and whether the amended consent needs a second PI signature before Monday. Speed matters because patients are waiting. Precision matters because regulators read slowly. The paradox is that the same environment that rewards thorough documentation punishes teams that retype everything into a second system nobody trusts.

via.email is built for that middle space: keep humans accountable while automating extraction, structure, and packaging from the correspondence you already have.

Agents that respect audit culture

Distill to Three (distill.to.three@via.email) gives investigators and sponsors a defensible snapshot when they will not read the whole chain on a phone between site visits. Extract Action Items (extract.action.items@via.email) surfaces who owes what after a monitor call so "we are aligned" does not mean three different interpretations on Tuesday. Convert to PDF (convert.to.pdf@via.email) helps when a thread needs to become an archival packet without someone rebuilding the story by hand. Build Compliance Evidence (build.compliance.evidence@via.email) supports the boring, valuable work of turning scattered notes into something an auditor can follow.

Add specialists with add@via.email (CC the agent) or explore departments at https://www.via.email/agents.

Why regulated email is a different category than "inbox zero"

Other industries treat mail as noise. In trials, mail is often evidence. That is closer to how lawyers already treat email as billable infrastructure and how physician leaders describe administrative load eating clinical time: the problem is not reading speed, it is cognitive load on people who cannot afford mistakes. Publishing workflows drown editors in submissions for a related reason: judgment-heavy review does not tolerate sloppy handoffs.

Clinical ops sits at the intersection. You are not looking for a chatbot that "sounds confident." You want assistance that keeps the human sign-off obvious while reducing transcription debt.

Receipts: FDA expectations and coordination load

FDA guidance on sponsor communication with review staff discusses email as a channel where clarity and recordkeeping matter. FDA SOPP 8119 lays out expectations for email in regulatory communications for biologics centers. ClinicalTrials.gov policy materials remind teams that documentation discipline is not optional.

NCATS materials on translational science highlight cross-site coordination burdens, which is a polite way of saying coordinators live in forwarded attachments. Harvard Business Review on digital exhaustion is relevant because monitors and CRAs were tired before AI showed up.

You cannot wish regulatory email away without replacing it with something equally auditable, which is why it persists. The practical upgrade is to make threads legible faster: clearer actions, cleaner summaries, packets that look like someone respected the inspection timeline.

Start with join@via.email (full name in the subject) or use help@via.email for one-off drafting inside a thread.